Hasil Pencarian - Elena Vishneva

  • Menampilkan 1 - 4 hasil dari 4
Perbaiki Hasil
  1. 1
    Prevalence of “allergy” as a false contraindication to vaccination in Russian parents

    Prevalence of “allergy” as a false contraindication to vaccination in Russian parents oleh Daria Chemakina, Leyla Namazova-Baranova, Elena Vishneva, Lilia Selimzianova, Marina Fedoseenko, Vera Kalugina

    Diterbitkan 2020-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Evaluating the efficacy of omalizumab therapy in a group of adolescents with chronic urticaria in real clinical practice

    Evaluating the efficacy of omalizumab therapy in a group of adolescents with chronic urticaria in real clinical practice oleh Vera Kalugina, Leyla Namazova-Baranova, Elena Vishneva, Anna Alekseeva, Elena Dobrynina, Julia Levina, Daria Chemakina

    Diterbitkan 2020-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    A non-randomized comparative study of olfactory and gustatory functions in children who recovered from COVID-19 (1-year follow-up)

    A non-randomized comparative study of olfactory and gustatory functions in children who recovered from COVID-19 (1-year follow-up) oleh Leyla Namazova-Baranova, Leyla Namazova-Baranova, George Karkashadze, Irina Zelenkova, Elena Vishneva, Elena Vishneva, Elena Kaytukova, Elena Kaytukova, Dina Rusinova, Dina Rusinova, Natalia Ustinova, Natalia Sergienko, Yulia Nesterova, Leonid Yatsyk, Dmitrii Kratko, Svetlana Gubanova, Viktor Gankovskiy, Tina Gogberashvili, Tatiana Konstantinidi, Darya Bushueva, Anastasia Rykunova, Elena Shirdanina, Svetlana Sadilloeva, Natalia Sergeeva, Anastasia Lamasova, Anastasia Lamasova, Elizaveta Leonova, Elizaveta Leonova, Alina Pankova, Alina Pankova, Ekaterina Dubonosova

    Diterbitkan 2022-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    LO-021 Interim safety and efficacy of subcutaneous (s.c.) dose ianalumab (VAY736; anti-BAFF-R mAb) administered monthly over 28 weeks in patients with systemic lupus erythematosus (SLE)

    LO-021 Interim safety and efficacy of subcutaneous (s.c.) dose ianalumab (VAY736; anti-BAFF-R mAb) administered monthly over 28 weeks in patients with systemic lupus erythematosus... oleh Yuko Kaneko, Masato Okada, Stephanie Finzel, Nan Shen, Elena Vishneva, Lingyun Sun, Bernadette Rojkovich, Alberta Hoi, Shin-Seok Lee, Piotr Leszczyński, Lie Dai, Rafal Wojciechowski, Cheng-Chung Wei, Katarzyna Romanowska-Prochnicka, Hiroshi Kaneko, Stanislav Ignatenko, Alexander Gordienko, Josefina Hernandez, Nancy Levin, Pongthorn Narongroeknawin, Hanna Ciferska, Masanari Kodera, Joung Liang Lan, Tunde Tarr, Yi Hsing Chen, Ajchara Koolvisoot, Eugeny Zotkin, Berta Paula magallares, Tirtha Sengupta, Carole Sips, Stephan Oliver

    Diterbitkan 2023-07-01
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: